{"organizations": [], "uuid": "049bc4d00309bc8e9a2594f687594991a0656f0a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biotest-new-data-from-monoclonal-a/brief-biotest-new-data-from-monoclonal-antibody-drug-conjugate-bt-062-idUSFWN1SA034", "country": "US", "domain_rank": 408, "title": "Biotest: New Data From Monoclonal Antibody-Drug-Conjugate BT-062", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.828, "site_type": "news", "published": "2018-05-03T13:09:00.000+03:00", "replies_count": 0, "uuid": "049bc4d00309bc8e9a2594f687594991a0656f0a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biotest-new-data-from-monoclonal-a/brief-biotest-new-data-from-monoclonal-antibody-drug-conjugate-bt-062-idUSFWN1SA034", "ord_in_thread": 0, "title": "Biotest: New Data From Monoclonal Antibody-Drug-Conjugate BT-062", "locations": [], "entities": {"persons": [{"name": "biotest", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "biotest ag", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3 (Reuters) - Biotest AG:\n* DGAP-NEWS: BIOTEST AG: NEW DATA FROM BIOTESTâ€™S MONOCLONAL ANTIBODY-DRUG-CONJUGATE (ADC) BT-062 IN THE THERAPY OF SOLID TUMORS\n* GOOD TOLERABILITY AND SIGNS OF EFFICACY IN PHASE I/IIA CLINICAL STUDY\n* VERY GOOD EFFECTIVENESS WHEN COMBINED WITH CHEMOTHERAPEUTIC AGENT IN PRECLINICAL STUDIES ON DIFFICULT TO TREAT BREAST CANCER\n* BIOTEST IS SEEKING INVESTORS FOR FURTHER DEVELOPMENT OF BT-062 Source text for Eikon: (Gdynia Newsroom)\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-03T13:09:00.000+03:00", "crawled": "2018-05-04T16:47:02.010+03:00", "highlightTitle": ""}